Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center

Key Points

• Durable disease control is achievable with systemic therapy in chordoma patients, particularly with the right selection.
• Patients treated with systemic therapy including tyrosine kinase inhibitors show promising responses, indicating their effectiveness.
• This observational analysis provides insights into existing treatments for chordoma, emphasizing real-world applicability.
• Future multicenter studies are crucial for enhancing treatment sequencing and improving outcomes for chordoma patients.